HLP003

The pharmacodynamic profile of HLP003, including its interactions with serotonin receptors and its effects in animals, is similar to that of psilocin. It is said to have a rapid onset of less than 15minutes and a duration of 4 to 6hours. ==Chemistry==

The exact chemical structure of HLP003 (i.e., which specific hydrogen atoms have been deuterated) does not yet seem to have been disclosed. This deuterated analogue of psilocin has been patented by Helus Pharma (formerly Cybin) as well as by Lennham Pharmaceuticals. Other deuterated drugs related to HLP003 or deupsilocin/d10-psilocin include the deuterated DMT analogues HLP004 (CYB004) and SPL028 and the deuterated phenethylamine HLP005 (CYB005). ==Research==

In 2024, HLP003 received a breakthrough therapy designation from the U.S. FDA and was in phase 3 clinical trials for major depressive disorder and is in the preclinical stage of development for alcoholism and other psychiatric disorders. Two phase 3 clinical trials for major depressive disorder are being initiated in November 2024 and February 2025. The drug is under development by Helus Pharma (formerly Cybin). == See also ==